The study by Song et al. [50], where lower systemic CCL3 levels correlated with increased CRC risk, suggesting impaired early immune function, is the only epidemiological study to examine pre-diagnostic blood samples in relation to CCL3 and CRC risk, whereas most other investigations have focused on diagnosed patients or tumor tissue, emphasizing progression or prognosis rather than risk. Here, CCL3 is linked to neoplasm.